Inovio Pharmaceuticals, Inc. (INO) Balance Sheet

The equity decline tracks cumulative operating cash outflows and net losses rather than any asset build, which suggests the balance sheet is weakening structurally rather than cyclically. Total assets have contracted from $133.8M to $49.4M over the same period, indicating that the company is consuming its capital base faster than it is replenishing it. Investors should monitor whether further losses push equity negative, as the 2025Q3 print already showed a deficit of $7.7M.

Total debt has declined gradually from $13.4M to $8.0M, so the increase in leverage is an equity-driven effect rather than new borrowing, which points to a balance sheet whose risk profile has shifted without any new financing decision. Liabilities of $45.0M against cash of $31.5M suggest that the company's obligations are approaching its liquid resources. Refinancing capacity cannot be assessed from the supplied data, so this warrants further investigation.

Given operating cash outflows of roughly $18M to $29M per quarter, the reported cash balance implies a runway measured in quarters rather than years, though the exact runway cannot be confirmed without management's stated funding plans. The current ratio near 1.0 leaves little margin for unexpected obligations. This pattern suggests the company relies on external capital to sustain operations, a dependency that warrants close monitoring.

The accumulated deficit of roughly $1.8B against current equity of $4.4M indicates that the equity base is largely the residual of past capital raises minus losses, with no retained profit cushion. The deficit has changed little across the period because the balance sheet shows the bulk of historical losses already recorded, so the recent equity erosion reflects current-period losses layered on that base. Dilution effects from any future raises cannot be measured from the supplied figures.